# ADULT MEDICATION GUIDELINE

## CYCLIZINE

This document should be read in conjunction with this DISCLAIMER

SAS Category A (tablet formulation only) (item requires approval by TGA)

| Presentation | Ampoule: 50mg/1mL  
| Tablet (SAS): 50mg |
| Dose | Prevention of post-operative nausea and vomiting  
| Route: IV/IM  
| 50 mg by approximately 20 minutes before the end of surgery.  
| May be given up to 3 times daily for a maximum of 48 hours after surgery. |
| Administration | IV injection  
| Dilution:  
| Dilute with 10mL Water for Injections or glucose 5%  
| Administration:  
| Administer by slow IV injection over 3-5 minutes.  
| Note: Rapid injection may cause stinging, burning and thrombophlebitis. |
| IM | Suitable |
| Pregnancy | 1st Trimester: Considered safe to use  
| 2nd Trimester: Considered safe to use  
| 3rd Trimester: Considered safe to use |
| Breastfeeding | Consider alternative |
| Monitoring | Not to be used for longer than 48 hours post-operatively.  
| Monitor for sedation.  
| Not compatible with 0.9% sodium chloride |
| Clinical Guidelines and Policies | WNHS Clinical Guideline: O&G: Post-Operative Nausea and Vomiting |
References


Keywords: Cyclizine, nausicalm, valoid, PONV, post-operative nausea and vomiting

Publishing: ☐ Intranet ☒ Internet

Document owner: Chief Pharmacist

Author / Reviewer: KEMH Pharmacy Department

Date first issued: Sept 2018

Version: 1.0

Last reviewed: Sept 2018

Next review date: Sept 2021

Endorsed by: Medicines and Therapeutics Committee

Date: Sept 2018

Standards Applicable: NSQHS Standards: 1 Governance, 4 Medication Safety

Printed or personally saved electronic copies of this document are considered uncontrolled. Access the current version from the WNHS website.

For any enquiries relating to this guideline, please email KEMH.PharmacyAdmin@health.wa.gov.au

© Department of Health Western Australia 2018